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Abstract
Background:  Extra-adrenal, intra-abdominal paraganglioma constitutes a rare neoplasm and,
moreover, its location in the greater omentum is extremely infrequent.
Case presentation: A 46-year-old woman with an unremarkable medical history presented with
an asymptomatic greater omentum mass that was discovered incidentally during ultrasonographic
evaluation due to menstrual disturbances. Clinical examination revealed a mobile, non-tender, well-
circumscribed mass in the right upper and lower abdominal quadrant. Blood tests were normal.
Contrast-enhanced abdominal computed tomography (CT) scan confirmed a huge (15 × 15 cm),
well-demarcated, solid and cystic, heterogeneously enhanced mass between the right liver lobe and
right kidney. Exploratory laparotomy revealed a large mass in the greater omentum. The tumor
was completely excised along with the greater omentum. Histopathology offered the diagnosis of
benign greater omentum paraganglioma. After an uneventful postoperative course, the patient was
discharged on the 4th postoperative day. She remains free of disease for 2 years as appears on
repeated CT scans as well as magnetic resonance imaging (MRI) and scintigraphy performed with
radiotracer-labeled metaiodobenzyl-guanidine (MIBG) scans.
Conclusion: This is the second reported case of greater omentum paraganglioma. Clinical and
imaging data of patients with extra-adrenal, intra-abdominal paragangliomas are variable while many
of them may be asymptomatic even when the lesion is quite large. Thorough histopathologic
evaluation is imperative for diagnosis and radical excision is the treatment of choice. Since there
are no definite microscopic criteria for the distinction between benign and malignant tumors,
prolonged follow-up is necessary.
Background
Extra-adrenal paragangliomas of the sympathoadrenal
neuroendocrine system consist 5%–15% of sporadic phe-
ochromocytomas and are located anywhere extending
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from the upper neck to the pelvic floor, parallel to the
autonomic nervous system [1,2]. Extra-adrenal, abdomi-
nal paragangliomas are divided into three groups: supe-
rior para-aortic, inferior para-aortic, and urinary bladder
tumors [2]. Rarely, extra-adrenal paragangliomas can
occur aberrantly outside this distribution. The annual
worldwide incidence of paragangliomas, as well as in
Greece, is approximately 1/300,000 [3,4].
Herein, we report such a case of a paraganglioma occur-
ring in the greater omentum in a 46-year-old woman
along with a review of the literature. To the best of our
knowledge, this is the second reported case of greater
omentum paraganglioma in the literature [5]. Apart from
its extremely infrequent location, the reported case is
important because of the rather huge diameter of the
tumor and the asymptomatic course of the patient prior to
diagnosis as well as the characteristic radiological and
pathological figures that are presented.
Case presentation
A 46-year-old woman with an unremarkable medical his-
tory presented with an asymptomatic greater omentum
mass incidentally found during ultrasonographic evalua-
tion due to menstrual disturbances. Clinical examination
showed a non-tender, mobile, well-circumscribed mass in
the right upper and lower abdominal quadrant. Esoph-
agogastroduodenoscopy revealed mild extrinsic compres-
sion of the stomach and duodenum. Contrast-enhanced
abdominal computed tomography (CT) scan, with oral
and i.v. contrast, confirmed a large (15 × 15 cm), well-
demarcated, solid and cystic, heterogeneously enhanced
mass between the right liver lobe and right kidney (Fig-
ures 1 and 2). Blood tests were normal, including levels of
serous neoplasmatic markers such as carbohydrate anti-
gen 19-9, carcinoembryonic antigen, carbohydrate anti-
gen 125, and a-feto-protein, as well as anti-echinoccocal
antibodies. Additionally, although no clinical or imaging
data suggested a pheochromocytoma, due to the close
anatomic relation of the tumor to the right kidney and
adrenal gland, blood levels of catecholamines, plasma-
free metanephrines, aldosterone, and rennin along with
24-hour urine levels of total catecholamines and their
metabolic products (vanillylmandelic acid and metane-
phrines) were measured and found to be within normal
limits. Due to the huge size of the mass, diagnostic lapar-
oscopy was considered impossible and, therefore, not per-
formed. Exploratory laparotomy revealed a large,
encapsulated, cystic and solid mass in the greater omen-
tum without any lymph node or distant metastasis. The
tumor was completely excised along with the greater
omentum.
On histopathologic evaluation, the tumor contained
small round cells (chief cells) arranged in well defined
nests, having a mixture of trabecular and alveolar pattern.
These groups of cells were separated by fibrovascular
septa, giving a characteristic "zellballen" nested pattern.
The tumor cells were polyhedral, with round or oval
nuclei, and contained intracytoplasmic hyaline globules;
no cytologic atypia or mitosis was observed, although
there were some nuclear pleomorphisms (Figure 3). No
local invasion, vascular invasion, confluent tumor necro-
sis or coarse nodularity was identified. Immunohisto-
chemically, the tumor cells revealed positive
Contrast enhanced CT scan showing heterogeneously  enhanced mass located above right kidney Figure 2
Contrast enhanced CT scan showing heterogeneously 
enhanced mass located above right kidney.
Contrast-enhanced abdominal CT scan, with oral and i.v.  contrast, shows a large (15 × 15 cm), well-demarcated, solid  and cystic, heterogeneously enhanced mass located between  the right lobe of the liver and the right kidney Figure 1
Contrast-enhanced abdominal CT scan, with oral and i.v. 
contrast, shows a large (15 × 15 cm), well-demarcated, solid 
and cystic, heterogeneously enhanced mass located between 
the right lobe of the liver and the right kidney.World Journal of Surgical Oncology 2007, 5:87 http://www.wjso.com/content/5/1/87
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immunostaining for chromogranin A and S-100 protein
(Figure 4). Additionally, positive staining for [Leu5]-
enkephalin, [Met5]-enkephalin, somatostatin, pancreatic
polypeptide, and vasoactive intestinal polypeptide (VIP)
was identified. A few nuclei were immunoreactive in Ki-
67/MIB-1 but proliferative activity as the percentage of Ki-
67 immunoreactive cells (proliferative index) was <1%
while immunostaining for cytokeratin, c-kit, and CD34
was negative. No telomerase activity (TA), human telom-
erase reverse transcriptase expression (hTERT: telomerase
catalytic subunit), topoisomerase IIa expression, or
mRNA expression of matrix metalloproteinase (MMP)-2
and EMMPRIN (extracellular matrix metalloproteinase
inducer) was detected. Based on histologic and immuno-
histochemical features, a diagnosis of benign greater
omentum paraganglioma was offered.
Due to histopathologic diagnosis, genetic testing for
familial paraganglioma, neurofibromatosis type 1, von
Hippel-Lindau disease, the Carney triad, multiple endo-
crine neoplasia type 2, and mutations of the succinate
dehydrogenase genes (SDHB, SDHC, and SDHD) was
performed that was negative.
After an uneventful postoperative course, the patient was
discharged on the 4th postoperative day. She remains free
of disease for 2 years as appears from repeated biochemi-
cal testing (plasma catecholamines, plasma-free metane-
phrines, urinary catecholamines, urinary vanillylmandelic
acid, urinary total metanephrines, urinary fractionated
metanephrines), CT scans as well as magnetic resonance
imaging (MRI) and scintigraphy performed with radi-
otracer-labeled metaiodobenzyl-guanidine (MIBG) scans.
Discussion
The paraganglion system is formed by numerous collec-
tions of neuroepithelial cells. Their common morpho-
logic characteristic is the presence of numerous
cytoplasmic neurosecretory granules containing catecho-
lamines. Paraganglioma is the generic term applied to
tumors of paraganglia regardless of location. Paraganglio-
mas of the adrenal medulla, the most common site of par-
agangliomas, are known as pheochromocytomas while
those located outside the adrenal gland as extra-adrenal
pheochromocytomas [6].
Extra-adrenal paraganglia are divided into two categories:
those related to the parasympathetic system and those
connected with the orthosympathetic system. The former,
usually nonchromaffin, lie in the head and neck including
the carotid body, intravagal, jugulotympanic, and medias-
tinal and aorticopulmonary paraganglia [7,8]. The latter
are chromaffin, associated with the peripheral sympa-
thetic nervous system, and secrete catecholamines in
response to sympathetic neural stimulation. They lie in
the paraaxial region of the trunk close to the paravertebral
and prevertebral ganglia or in the connective tissue adja-
cent to pelvic organs, predominating along the thoraco-
lumbar paraaortic region in the retroperitoneum [9,10].
The adrenal medulla and the organs of Zuckerkandl are
the only ones visible to the naked eye [6,10].
Extra-adrenal, intra-abdominal paragangliomas are
divided into three groups: superior para-aortic, inferior
para-aortic, and urinary bladder paragangliomas [9,11].
Rarely, paragangliomas have been described in other unu-
sual sites, such as the gallbladder [12], mesentery [13],
kidney [14], prostate [15], and ovary [16]. We hypothe-
Photomicrograph of paraganglioma showing positive immu- nostaining for chromogranin A. Streptavidin-alkaline phos- phatase reaction (× 20). Figure 4
Photomicrograph of paraganglioma showing positive immu-
nostaining for chromogranin A. Streptavidin-alkaline phos-
phatase reaction (× 20).
Photomicrograph showing paraganglioma with nuclear pleo- morphism and hyperchromasia (HE × 20) Figure 3
Photomicrograph showing paraganglioma with nuclear pleo-
morphism and hyperchromasia (HE × 20).World Journal of Surgical Oncology 2007, 5:87 http://www.wjso.com/content/5/1/87
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size that the paraganglioma in our patient was derived
from the paraganglionic cells by vertebral migration from
the root of superior mesenteric artery. The development of
a paraganglioma in the greater omentum is extremely rare
and this case represents the second report in the literature
[5]. As with other paragangliomas described outside the
distribution of paraganglionic tissue, our case may be
explained by the migration patterns of the widely dis-
persed neural crest cells.
Paragangliomas may be hereditary and can be associated
with familial paraganglioma, neurofibromatosis type 1,
von Hippel-Lindau disease, the Carney triad, multiple
endocrine neoplasia type 2, and mutations of the succi-
nate dehydrogenase genes (SDHB, SDHC, and SDHD)
[1]. Genetic testing should, therefore, be considered in all
patients with paraganglioma. In the presented case,
genetic testing was performed and was negative.
Histologically, paraganglia contain nests of neuroendo-
crine cells surrounded by sustenacular cells. This pattern is
most clearly seen in parasympathetic paraganglia as the
characteristic "zellballen". In sympathetic paraganglia,
neuroendocrine cells are referred to as chromaffin cells
and in parasympathetic as chief cells. These cells are
immunopositive for neuroendocrine markers including
synaptophysin and chromogranin A and for several neu-
ropeptides. Features that may predict malignancy include
extra-adrenal location, confluent tumor necrosis, vascular
invasion, local invasion, coarse nodularity, and absence
of hyaline globules [17]. Moreover, decreased expression
of neuropeptides and, particularly, negative staining for
enkephalins, somatostatin, pancreatic polypeptide, and
VIP have been associated with malignancy [18]. Although
the presented tumor was extra-adrenal, the presence of
hyaline globules and the absence of confluent tumor
necrosis, vascular invasion, local invasion, and coarse
nodularity along with the positive staining for the above-
mentioned polypeptides show the benign nature of this
lesion.
Most patients with extra-adrenal, abdominal paraganglio-
mas present with abdominal pain or a palpable abdomi-
nal mass [19]; however, they may be asymptomatic even
when the lesion is large and the tumor is incidentally
found during radiographic evaluation for other reasons,
such as the presented patient. Other symptoms may be
nausea, vomiting, diarrhea, abdominal distension, and
weight loss. Increased catecholamine secretion in func-
tional tumors is responsible for symptoms such as hyper-
tension, flashing, sweating, headache, diaphoresis,
anxiety, tachycardia, or palpitations [9,11,19].
Even though imaging studies are helpful, diagnosis of
extra-adrenal, intra-abdominal paragangliomas can be
safely done only with careful histologic and immunohis-
tochemical evaluation. Contrast-enhanced abdominal CT
scan is useful for diagnosis; however, no CT feature
unique for paragangliomas has been found [11]. Abdom-
inal MRI and MIBG are essential in localization and char-
acterization of paragangliomas while MRI has the highest
sensitivity in detection of extra-adrenal paragangliomas as
well as pheochromocytomas [20,21].
The majority of abdominal tumors are benign; 10%–50%
of intra-abdominal, extra-adrenal paragangliomas are
reported to be malignant [9-11,19,22]. Malignant forms
frequently develop distant metastases in lung, liver, and
lymph nodes. Annual postoperative biochemical testing
(plasma catecholamines, plasma-free metanephrines, uri-
nary catecholamines, urinary vanillylmandelic acid, uri-
nary total metanephrines, and urinary fractionated
metanephrines), CT scans as well as MRI and MIBG scans
are essential for assessment for metastatic disease, tumor
recurrence or delayed appearance of multiple primary
tumors [1].
Clinical and histological distinction between benign and
malignant cases is difficult [9,23,24]. The only proof of
malignancy is the presence of metastases or local invasion
while in localized tumors there are no absolute criteria for
predicting malignant potential. This principle has the
drawback that some cases will initially be classified as
benign and then reclassified as malignant if metastases are
identified at follow-up. There is, therefore, a clear need for
additional diagnostic tools to enable detection of malig-
nant cases at initial surgery. Additional diagnostic markers
would be valuable, but, up to date, no reliable prognostic
markers have been identified [23,24]. Although several
markers such as immunohistochemical expression of the
cell proliferation marker Ki-67/MIB-1, telomerase activity,
hTERT expression, topoisomerase IIa expression, and
mRNA expression of MMP-2 and EMMPRIN metallopro-
teinases have shown promising results, they need further
evaluation. Even though these markers seem to be very
valuable, particularly when combined with histopathol-
ogy, no single test or combination of tests has yielded suf-
ficiently high sensitivity and specificity to result in
widespread acceptance in everyday clinical practice [22-
26]. Due to the rarity of the tumor, multicenter studies are
probably necessary in this effort [24]. The very low prolif-
eration index (<1%) found in the presented case and the
fact that no telomerase activity, hTERT expression, topoi-
somerase IIa expression, or mRNA expression of MMP-2
and EMMPRIN metalloproteinases was identified show
the benign nature of this lesion.
The treatment of choice for paragangliomas is complete
surgical resection. Traditional treatment consists of open
exploration and resection. However, laparoscopic man-World Journal of Surgical Oncology 2007, 5:87 http://www.wjso.com/content/5/1/87
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agement is nowadays increasingly being used for their
management due to the advances in laparoscopic tech-
nique and refined preoperative imaging even though few
studies regarding the laparoscopic treatment of extra-adre-
nal intra-abdominal paragangliomas exist in the literature
because of the rarity of this clinical entity [1]. Intraopera-
tive ultrasound is considered an invaluable tool for lapar-
oscopic surgeons in these cases. In these studies of
laparoscopic management, encouraging results are pre-
sented; it should be mentioned, however, that all tumors
were less than 4 cm [1]. In the presented patient, due to
the huge size of the tumor, laparoscopy was considered
impossible and, therefore, not performed.
Since clinical presentation and imaging data of these
patients are variable and non specific, histological distinc-
tion between benign and malignant cases as well as pre-
diction of malignant potential are difficult, and local
recurrence or distant metastases are not infrequent, a
multidisciplinary approach regarding effective diagnosis,
management and follow-up is essential and should
involve the close collaboration of endocrinologists, sur-
geons, anesthesiologists, geneticists, laboratory special-
ists, radiologists, oncologists, and pathologists.
Conclusion
Paraganglioma of the greater omentum is extremely infre-
quent. Recognition of this tumor as a cause of an abdom-
inal mass is important. Clinical and imaging data of
patients with extra-adrenal, intra-abdominal paraganglio-
mas are highly variable and non specific while many of
them may be asymptomatic even when the lesion is quite
large, such as the presented case. Thorough histological
and immunohistochemical evaluation is, therefore,
imperative and the only safe modality for diagnosis. The
first line treatment is surgical resection, while chemother-
apy and radiotherapy seem to be useless in benign lesions
[19,22]. Since there are no definite microscopic criteria for
the distinction between benign and malignant tumors,
radical excision is the treatment of choice and prolonged
follow-up is necessary.
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